The 7 most recent market catalysts affecting $ABVX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 85
These Analysts Slash Their Forecasts On Abivax Following H1 Results
Abivax (ABVX) released its H1 2023 financial results, showing a larger-than-expected loss per share of $2.43 against an estimated $1.08, which is a significant negative surprise. H…
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
Truist Securities Maintains Buy on Abivax, Lowers Price Target to $151
This filing discloses that Truist Securities, through analyst Gregory Renza, has reiterated a 'Buy' rating for Abivax (ABVX) but has marginally reduced its price target from $155 t…
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118
Wedbush analyst David Nierengarten has reiterated a 'Neutral' rating on Abivax but significantly reduced the price target from $140 to $118. This action indicates a more conservati…
Sep 21, 2026
Corporate Catalyst
Bearish
Impact 92
Abivax H1 EPS $(2.43) Misses $(1.08) Estimate, Sales $2.959M Beat $1.860M Estimate
Abivax's H1 earnings report presents a mixed bag for investors. The substantial EPS miss, with losses more than double the analyst consensus, is a significant negative signal, indi…
Sep 14, 2026
Corporate Catalyst
Bearish
Impact 65
Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
This filing announces that Abivax (ABVX) will release its first-half earnings report after the market close on Monday, September 21st. The key information is the consensus analyst …
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
Goldman Sachs Initiates Coverage On Abivax with Buy Rating, Announces Price Target of $155
Goldman Sachs, a prominent investment bank, has initiated coverage on Abivax (ABVX) with a 'Buy' rating and a $155 price target. This event is significant because analyst coverage …
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 95
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La Lettre
The filing indicates that Abivax has re-engaged Centerview Partners, a prominent investment bank, specifically to facilitate discussions with 'Big Pharma' companies regarding a pot…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.